Background/Objectives: Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of morbidity and mortality worldwide. Between 35% and 65% of NSCLC patients experience nutritional problems or malnutrition, which significantly affects their prognosis and quality of life. This study aims to describe the nutritional status and body composition of NSCLC patients treated with osimertinib, an oral tyrosine kinase inhibitor, while also assessing the prevalence of sarcopenia, presarcopenia, and dynapenia. Additionally, we explore the relationship between dose-limiting toxicities (DLTs) and nutritional status, as well as the impact of nutritional status on quality of life using the EQ-5D scale. Methods: A cross-sectional, observational study was conducted in 25 adult patients diagnosed with NSCLC treated with osimertinib under pharmacotherapeutic follow-up in the Pharmacy Consultations of a tertiary-level hospital. Anthropometric parameters, body composition (via bioimpedance analysis), and muscle functionality (via dynamometry) were assessed. Quality of life was evaluated using the EQ-5D scale. Results: The results showed that 36% of patients were malnourished, 4% had sarcopenia, 8% were presarcopenic, and 20% had dynapenia. Patients with DLTs exhibited significantly lower values of fat-free mass and the fat-free mass index, suggesting a relationship between low muscle mass and increased toxicities. Conclusions: These findings underscore the importance of early, individualized nutritional interventions in NSCLC patients treated with osimertinib to improve nutritional status and optimize oncological outcomes. Further research with larger cohorts and longitudinal designs is necessary to confirm these findings.

Background: Nirmatrelvir/ritonavir was authorised for the treatment of COVID-19 patients, despite limited evidence regarding its effectiveness, adverse events or interactions. Objectives: Main objective is to assess the impact of pharmaceutical care interventions delivered via telemedicine in patients who started treatment with nirmatrelvir/ritonavir. Secondary objectives are to describe its effectiveness, to analyse its adverse effects, to describe the potential interactions and to analyse patients’ adherence. Method: A cohort, prospective and multicentre study was conducted from April to November 2022. Adult patients who initiated nirmatrelvir/ritonavir were included. A descriptive study of the pharmacist interventions, adverse effects, clinical outcomes, interactions and treatment adherence was carried out. Pharmaceutical care was provided through a telephone call. Results: 281 patients were included and 100% of them received telephone information. A total of 349 interventions of pharmaceutical care were carried out. Sixty-four interventions were related to dose reduction. A total of 285 potential interactions were detected. Sixty-five pharmacist interventions were related to potential severe interaction, that led to discontinuation of the concomitant medication in 56 cases (86,2%) All the pharmacist interventions were accepted by the prescribers. A total of 112 (39.9%) patients experienced some adverse effects. Seventeen patients were hospitalised (6.0%) and five deaths were recorded (1.7%). The 95.3% of the patients reported a total adherence. Conclusions: Telepharmacy is a powerful tool for the safe management of the nirmatrelvir/ritonavir. Hospital pharmacists were able to prevent severe potential interactions. The percentages of hospitalised patients, deceased and adverse effects were higher than those reported in pivotal trials. Most patients reported total adherence to the treatment.